GuideSurgery
30-day and 2-year survival after infrainguinal revascularisation for chronic limb-threatening ischaemia (VQI)
VQI registry models estimating survival after infrainguinal bypass or endovascular treatment for chronic limb-threatening ischaemia.
Updated 3 November 2026
When to use it
Choosing between bypass and endovascular treatment in CLTI: open surgery pays off more in those expected to survive beyond 2 years.
What it is
Cox models with preoperative variables derived from 38,470 Vascular Quality Initiative patients (2003–2017) with CLTI treated with bypass (37%) or endovascular intervention (63%). They model survival at 30 days, 2 years and 5 years.
Keep reading in the app
- Predictors
- Published risk categories
- Practical use
Practical tip
In the BASIL trial, the bypass advantage appeared in those surviving more than 2 years.
2 more practical tips in the app.
Reference
- Simons JP, Schanzer A, Flahive JM, et al. Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. J Vasc Surg. 2019;69(6S):137S-151S.e3.
- Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-125S.e40.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
